

18th May, 2026

BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Successful closure of US FDA Inspection at Piramal Pharma's manufacturing facility located at Digwal, Telangana, India

Dear Sir / Madam,

Kindly refer to our letter dated 14th February, 2026 regarding US FDA Inspection at Piramal Pharma Limited's manufacturing facility located at Digwal, Telangana, India.

In furtherance to the aforementioned intimation, this is to inform you that US FDA has issued an Establishment Inspection Report (EIR) for the said manufacturing facility and the inspection has now been successfully closed by the US FDA.

The intimation is being submitted today being the first working day after receipt of the said EIR.

This is for your information and records.

Thank you.

Yours truly,
For **Piramal Pharma Limited**

Maneesh Sharma
Company Secretary and Compliance Officer